Atossa Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on August 14, 2023
August 08 2023 - 9:00AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company developing innovative medicines to
address significant unmet needs in cancer, today announced that it
will provide a business update and report financial results for the
second quarter 2023 on Monday, August 14, 2023. Company management
will host a conference call to review the results at 9:00 a.m. ET /
6:00 a.m. PT on August 14, 2023.
Second Quarter 2023 Conference Call
DetailsDate: Monday, August 14, 2023Time: 9:00 a.m. ET /
6:00 a.m. PTParticipant
Registration: https://edge.media-server.com/mmc/p/2qtrmqz3
Interested participants should register for the
conference call in advance of the call’s start time.
Following the call, a recording will be made
available on the investor relations page of Atossa’s website:
https://investors.atossatherapeutics.com
About Atossa TherapeuticsAtossa
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing innovative medicines in areas of significant unmet
medical need in oncology with a focus on breast cancer. For more
information, please visit www.atossatherapeutics.com.
Contact:Eric Van ZantenVP,
Investor and Public
Relations610-529-6219eric.vanzanten@atossainc.com
FORWARD LOOKING STATEMENTS
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with the expected timing of
releasing data, any variation between interim and final clinical
results, actions and inactions by the FDA, the outcome or timing of
regulatory approvals needed by Atossa including those needed to
commence studies of (Z)-endoxifen, anticipated progress on Atossa’s
(Z)-endoxifen development program, anticipated rate of patient
enrollment, estimated market size of drugs under development, the
safety and efficacy of Atossa’s products, performance of clinical
research organizations and investigators, obstacles resulting from
proprietary rights held by others such as patent rights, whether
reduction in breast density or in Ki-67 or any other result from a
neoadjuvant study is an approvable endpoint for (Z)-endoxifen,
whether Atossa can complete acquisitions, anticipated working
capital needs and expectations around the sufficiency of our cash
reserves, and other risks detailed from time to time in Atossa’s
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024